Updated:
Modi Ventures
Modi Ventures invests in funds and founders at the intersection of technology and biology and at the forefront of the emergent bioeconomy. It makes early stage...
Modi Ventures
Modi Ventures invests in funds and founders at the intersection of technology and biology and at the forefront of the emergent bioeconomy. It makes early stage investments in technology platforms that have a positive impact on health, with a deep focus on opportunities that leverage AI, microfluidics (hardware), multiomics, precision medicine, synbio, gene editing, and living therapies.
General information
Firm type
Venture Capital
Year founded
2023
Location
Region
North America
Country
United States
City
Sugar Land
Corporate office
Sugar Land, TX, United States
Principals
Sahir Ali
Sector focus
Frequently asked questions
Does Modi Ventures invest directly in startups, or is it exclusively a fund-of-funds?
Modi Ventures operates a hybrid model. It makes direct seed-stage investments in early-stage companies — 44 as reported on its website — and it also commits capital to external venture funds, with 30 fund positions disclosed. The firm does not publish the proportion of capital allocated to each lane.
What investment stages does Modi Ventures target?
The firm targets early-stage investments, specifically seed stage, across both its direct startup portfolio and its fund commitments. The website lists no growth-stage or late-stage positions. The portfolio companies, such as Glyphic Biotechnologies and Kamau Therapeutics, are clinical-stage or earlier.
Which sectors does Modi Ventures focus on?
Modi Ventures concentrates on the intersection of technology and biology. Its website names AI applied to drug discovery, microfluidics hardware, multiomics, precision medicine, synthetic biology, gene editing, and living therapies as explicit focus areas. The firm does not invest in generalist health-tech or traditional biotech outside of AI-enabled platforms.
What are Modi Ventures' most notable portfolio companies?
Disclosed direct portfolio companies include Generate Biomedicines, which builds generative AI models for protein-based therapeutics; Glyphic Biotechnologies, developing next-generation protein sequencing; Harbinger Health, focused on AI-enabled cancer screening; Kamau Therapeutics, a gene-correction company; and Brainomix, an AI-powered medical imaging platform. Fund-level holdings are not publicly named.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: